Ovarian cancers are thought to result from the accumulation of multiple genetic aberrations that transform ovarian and/or fallopian tube surface epithelial cells, allowing for their abnormal growth, proliferation and metastasis. In the report presented here, we carried out genome-wide copy-number analysis using comparative genomic hybridization on a panel of mouse ovarian cancer (OVCA) cell lines previously established in our laboratory. We identified a recurrent focal amplification on mouse chromosomal region 2qB, which contains the LIM-homeodomain-containing transcription factor 1B (Lmx1b) gene. LMX1B is not expressed in normal human ovary, but is expressed in many human OVCA cell lines and primary tumors. High expression of LMX1B correlates with poor outcome. To clarify the role of LMX1B in ovarian carcinogenesis, we transduced LMX1B into a panel of mouse and human OVCA cell lines and demonstrated that LMX1B strongly promotes migration of cancer cells in culture and promotes xenograft growth in nude mice. Conversely, knockdown of LMX1B in a human cell line with endogenous high expression of LMX1B inhibits cell migration in vitro and tumor growth in vivo. Microarray analysis of cells overexpressing LMX1B identified the nuclear factor (NF)-kB pathway as a potential mediator of tumor progression and subsequent treatment of NFkB inhibitor decreased the migratory capacity of these cells. Thus, our data demonstrate that LMX1B is a novel oncogene in OVCA pathogenesis.
INTRODUCTION
Human ovarian cancers display a multitude of genetic abnormalities including deletions, amplifications and structural rearrangements as exemplified by the results of The Cancer Genome Atlas (TCGA) project. 1 Discovery of these aberrations and understanding how they contribute to the pathophysiology of ovarian cancer are necessary for improvements in diagnosis and therapy. 2, 3 Genomic aberrations arise recurrently on some chromosomal locations in cancer cells, indicating that these locations may contain genes that are important for cancer progression. The development of array-based comparative genomic hybridization (aCGH) has provided genome-wide high-resolution detection of alterations of DNA copy number. 4 This approach has enabled the identification of a large number of genomic loci that undergo amplifications and deletions during the process of tumorigenesis in various cancer types, including human ovarian carcinomas. [5] [6] [7] Several genes, including MYC, AKT2, PIK3CA and ERBB2, which are known to contribute to the pathophysiology of ovarian cancer (OVCA) are located in regions of recurrent DNA copy number aberrations, suggesting that other regions of recurrent amplifications and deletions contain putative oncogenes and tumor suppressor genes, respectively. Indeed, recent efforts to characterize some of these alterations have lead to identification of novel cancer genes, such as RAB25 8 and MDS1/EVI1, 9 that are associated with OVCA. However, copy number alterations obtained by aCGH analysis of human primary tumors are often large, involving complex structural rearrangements and span several megabases of DNA sequences. 1 The high degree of genomic complexity of human ovarian tumors highlights the need for biological systems capable of distinguishing 'driver' cancer genes that are responsible for the neoplastic transformation process from 'passenger' genes. 10 Molecular mechanisms that control important biological processes are often preserved during evolution. Thus, cross-species genomic analysis can be used as a biological filter to identify relevant genomic alterations that lead to cancer development. The utility of comparative oncogenomic approaches for efficient identification of driver cancer genes was recently demonstrated by the identification of several new oncogenes in regions that are commonly amplified in mouse and human melanomas 11 and hepatocellular carcinomas. 12 It is expected that cross-species comparison will greatly facilitate identification of other relevant genes that are involved in human cancer progression.
Mouse ovarian epithelial tumor cell lines containing various combinations of genetic alterations in the p53, c-myc, K-ras, Akt and BRCA1 genes have been shown to produce ovarian tumors in vivo resembling the serous histology. [13] [14] [15] These cell lines are ideal for dissecting pathways for targeted therapy as well as useful for identifying novel genes that are involved in cancer progression. We hypothesized that besides the retrovirally transduced initiating genetic events that were used to generate this model, additional genetic events presumably occurred during tumor development in nude mice. In line with this hypothesis, the secondary cell lines derived from the xenograft tumors exhibited an enhanced tumorigenic potential both in vitro and in vivo. 14, 15 We therefore reasoned that high-resolution aCGH analysis of these secondary tumor cell lines would be ideal for identifying novel genetic events associated with OVCA progression and metastasis. In the report presented here, we carried out a high-resolution genome-wide copy-number analysis using aCGH on a panel of mouse OVCA cell lines with known initiating genetic events. 14, 15 As a result of this analysis, we identified a novel recurrent focal amplification on mouse chromosome 2B containing a single gene, the LIM domain containing transcription factor 1B (LMX1B); the syntenic region of human chromosome 9q33.3. Transcription factors have been known to contribute to tumorigenesis owing to their role in regulation of gene expression. 16 In ovarian cancer, transcription factors that are commonly mutated and amplified include p53, RB1 and MYC. 1 Developmental transcription factors that are involved in ovarian cancers are HOXB13, 17 SHH 18 and the NOTCH superfamily 19 among others. In the current study, we focus on LMX1B, which is one of the essential transcription factors involved in the development of midbrain. 20, 21 We found that LMX1B was not expressed in normal ovarian surface epithelium, but showed moderate to high level of expression in several human OVCA cell lines and primary tumors. To test the role of LMX1B in ovarian carcinogenesis, we ectopically expressed LMX1B and found that LMX1B overexpression strongly induces migration of cancer cells in vitro and accelerates tumor growth in vivo. Conversely, knockdown of LMX1B in human OVCA line with endogenous high expression of LMX1B inhibits cell migration in vitro and tumor growth in vivo. Thus, our results demonstrate that LMX1B is a novel oncogene which has important roles in ovarian cancer progression. Ten genetically defined mouse OVCA lines T1, T11, T111, T2, T22,  T222, T3, TBR2, TBR5 and TBR6 (Supplementary Table 1) were used for copy number alteration analysis. The status of the Brca1 and the p53 gene in these genetically defined cancer cell lines provided excellent internal controls for aCGH data validation. Mouse OVCA cell lines TBR2, TBR5 and TBR6 were derived from mouse cell lines with a conditional deletion of the Brca1 exon 11. 15 Consistent with this, aCGH probe that mapped to the Brca1 exon 11 detected decreased copy number (Supplementary Figure 1A) in OVCA cell lines . The OVCA cell lines T1, T11, T111,  T2, T22, T222 and T3 were derived from mice with a conventional  knockout of the p53 exons 2-5,  22 whereas cancer cell lines TBR2,  TBR5 and TBR6 were derived from mice with a conditional  deletion of the p53 exons 2-10 23 (Supplementary Figure 1B) . The p53 probe in the array falls outside the deletion in the conventional p53 knockout mouse; hence, the deletion of p53 was detected in the conditional p53 knockout only.
RESULTS

aCGH analysis of mouse ovarian cancer cell lines
After successful validation of the aCGH data, we analyzed individual chromosomal aberrations in each sample. aCGH analysis identified large regions of chromosomal losses and gains. It also readily detected focal amplifications and deletions, including homozygous deletions ( Supplementary Figures 2A and B) .
Amplification of Lmx1b gene in mouse OVCA cell lines We observed a focal amplification in Lmx1b locus in two cell lines (log2 ratio 42.5) and copy number increase in three cell lines (log2 ratio 41.5) (Figures 1a and b) . In human serous ovarian tumors, LMX1B is also amplified, although less frequently ( Figure 1a) . We decided to further study this gene for the following reasons: (1) this was a focal and recurrent amplification locus containing a single gene. (2) LMX1B is expressed during embryonic development but its expression is turned off in most adult tissues, except for podocytes in the kidney (Figure 1d ). Thus, amplification of this gene in cancer cells is likely to be of functional significance. (3) Although the possible involvement of LMX1B in cancer has never been reported, it is becoming increasingly appreciated that many developmentally important transcription factors, such as FOXC2, HOXB13 and Twist exhibit strong protumorigenic or prometastatic function in breast and ovarian cancers. 17, 24, 25 We thus hypothesized that similar paradigm may also hold true for LMX1B.
aCGH results were validated using two-color fluorescence in situ hybridization. BAC clone RP23-65G6 containing the entire mouse Lmx1b gene and BAC clone RP23-60M5 mapping to 2qH4 used as control probe confirmed amplification of Lmx1b gene (Figure 1c) . Previous studies have shown that Lmx1b is highly expressed during mouse embryogenesis in the limb buds, isthmus organizer and kidney. 26, 27 In adult mice however, its expression is low in almost all the tissues (including ovaries) except for podocytes in the kidney. We confirmed this by quantitative RT-PCR using RNA from multiple adult mouse tissue types (Figure 1d) . At the DNA level, there is a high degree of homology between human and mouse LMX1B genes; and at the protein level, human and mouse LMX1B proteins are almost identical (1 amino acid difference out of 300 amino acids).
Analysis of LMX1B expression in human OVCA cell lines and primary tumors To determine whether LMX1B is expressed in human OVCA cell lines and primary tumors, we analyzed by qRT-PCR a panel of 15 OVCA cell lines and 45 primary tumor samples with clinical follow up information (Massachusetts General Hospital cohort). Compared with T29, an immortalized human ovarian surface epithelial cell line, more than twofold expression of LMX1B was found in 7/ 15 cell lines (Figure 2a ) and relative to the tumor with the lowest expression, more than 15-fold expression of LMX1B was detected in 29/45 primary tumors (Figure 2b) . Notably, four primary tumors exhibited more than 100-800-fold increase in LMX1B expression. This observation was further validated in an independent microarray dataset generated using 53 micro-dissected OVCA tissues and 9 ovarian surface epithelial cells (P ¼ 0.02) (Figure 2c) . 28 Of the 53 samples, 5 also exhibited more than 100-fold increase in LMX1B expression. We then sought to identify if there was any correlation between LMX1B expression level and clinical outcome. Primary tumor samples from the Massachusetts General Hospital cohort were divided into low-and high expressing subgroups using the median expression fold change (Figure 2d) . We found that patients with higher LMX1B expression had a significantly poor overall survival compared with the low expressing group (Po0.05) (Figure 2e ). These results indicate that LMX1B may be an important player in tumor progression in a subset of OVCA patients.
Ectopic expression of LMX1B promotes tumorigenesis Based on LMX1B expression analysis in primary tumors, we reasoned that ectopic expression of LMX1B gene in OVCA cells will render them more malignant. To test this hypothesis, the coding sequence of human LMX1B was cloned into a retroviral expression vector. Virus particles containing LMX1B were generated to infect various cancer cell lines, including mouse OVCA cell lines C1, C2, BR5 and human OVCA cell lines OVCAR5 and OV90. In addition, non-tumorigenic NIH3T3 mouse fibroblast cells were included to directly test the transforming ability of LMX1B. The ectopic expression of LMX1B after puromycin selection was confirmed by RT-PCR (data not shown).
To test whether LMX1B affects tumor cell biology, we performed proliferation, soft agar colony formation and cell migration assay on the mouse and human cell lines expressing LMX1B along with their corresponding GFP-expressing cells as control. No obvious difference was observed in cell proliferation LMX1B as an oncogene in ovarian cancer L He et al rate and soft agar colony forming ability between LMX1B-expressing and GFP-expressing control cells (data not shown). However, LMX1B-expressing cells had a higher migratory ability ( Figure 3a) . To test the hypothesis that expression of LMX1B in vivo may lead to a higher rate of tumor growth, we injected cells expressing either LMX1B or the GFP control into flanks of nude mice or NOD/SCID mice. In all cell lines tested, including NIH3T3 cells, LMX1B overexpression accelerated tumor growth compared with GFP-expressing control cells within 2-8 weeks post injection (Figures 3b-e) , regardless of the species and genetic make-up of the cell lines. This observation was reproduced by intraperitoneal injections of OVCAR5 cells expressing GFP and LMX1B (Figure 3f ). Notably, in BR5 and NIH3T3 cells (Figure 3c ), no viable tumor could be detected except in one mouse in the GFP-expressing control lines within the window of time of our experiments (up to 10 weeks). Further histological analysis showed that the overall pathology of the control GFP-expressing tumors versus LMX1B-expressing tumors were similar, resembling human serous type epithelial cancer (except for NIH3T3 cells) (Supplementary Figures 3A-D) . Based on these results, we conclude that LMX1B acts as an oncogene and that it promotes tumor progression.
LMX1B knockdown abrogates tumor growth in vivo As overexpression of LMX1B accelerated tumor growth in vivo, we reasoned that knocking down LMX1B in OVCA cells with high endogenous LMX1B expression would negatively affect their tumorigenic potential. To test this hypothesis, we knocked down endogenous LMX1B using lentiviral-mediated shRNA constructs in TOV112D OVCA cells as these cells were among the high expressor lines determined by qRT-PCR analysis (Figure 2a) . Two shRNA constructs, sh-LMX1B-B10 and sh-LMX1B-C01 produced ). In order to confirm LMX1B knockdown at the protein level, LMX1B complementary DNA was cloned into a pCMV6-Entry (C-terminal Myc and FLAG-tagged) vector and co-transfected with the hairpins that produced efficient knockdown. Western blotting using a monoclonal anti-FLAG antibody showed that the exogenous tagged LMX1B protein was much lower in cells co-transfected with either of the two hairpins (Figure 4b ). Inhibition of LMX1B expression in TOV112D cells using either of the two shRNA constructs resulted in lower cell migration capacity (Figure 4c ), although no significant difference was observed in proliferation and colony forming ability (not shown). Furthermore, when planted into the flanks of NOD/SCID mice, tumor growth was almost completely abrogated for TOV112D cells transduced with either of the two shRNA constructs, compared with the control shRNA against GFP (Figures 4d-e) . Thus, suppression of LMX1B in TOV112D cells inhibits tumor growth in vivo. We conclude that endogenous LMX1B has an essential role in tumor progression.
Global gene expression analysis of cells overexpressing LMX1B identifies the NFkB pathway as a potential mediator of tumor progression Expression profiling of OVCAR5 and OV90 cells overexpressing LMX1B compared with the GFP control cells identified 863 differentially expressed genes (P ¼ 0.001) (Figure 5a, Supplementary Table 2 ). In order to identify molecular and biological processes mediated by LMX1B, gene set enrichment analysis of the 863 differentially expressed genes was performed using PathwayStudio software version 7.0. (http://www.ariadnegenomics.com/ company/news/all-news/article/ariadne-launches-pathway-studioRversion-7/). Gene set enrichment analysis linked these genes into 28 different biological processes listed in Table 1 . Among these gene sets, response to cytokine stimulus included 36 genes and had the highest median fold-change of 15.25. Further examination revealed majority of the genes in this set belong to the nuclear factor (NF)-kB pathway and identified the NFkB pathway as a potential mediator of tumor progression. To confirm the accuracy of microarray results, we validated 16 genes by qRT-PCR (Table 2 , Figure 5b and Supplementary Figure 4A) . Of the 16 genes, 13 were validated in OVCAR5 (81%) and 15 were validated in OV90 cells (94%) indicating a significant correlation between microarray and qRT-PCR data. Of these 16 genes, 11 belong to the NFkB pathway and are known to have altered expression in high-grade serous tumors. 29 The NFkB activity is known to increase the transcription of cytokines such as interleukin (IL)-6 and IL8. In OVCAR5-LMX1B cells, both IL6 and IL8 were expressed more than 75-fold and 35-fold, respectively, compared with OVCAR5-GFP cells (Figure 5b) . In OV90-LMX1B cells, IL8 was expressed 14-fold more compared with OV90-GFP cells (Figure 5b) . In order to functionally validate the involvement of NFkB activity in the production of IL6 and IL8, we used a NFkB inhibitor on OVCAR5-LMX1B and OV90-LMX1B cells. Cells were treated with 20 nM QNZ, an NFkB transactivation inhibitor for 24 h. The RNA was isolated and qRT-PCR was performed. As shown in Figure 5c , QNZ treatment reversed LMX1B-induced upregulation of the NFkB pathway genes IL6, IL8, NFKB1, PTGS2 and TNFAIP6 but failed to alter the expression of the non-NFkB pathway genes DTL, ERBB3 and FOXC1, suggesting that the production of cytokines is dependent on NFkB transcriptional activation. In addition, OVCAR5-LMX1B and OV90-LMX1B cells treated with QNZ showed a significant reduction in their migratory ability (Figure 5d ). At this concentration and time scale, no alteration in cell viability was observed (data not shown). Finally, western blotting analysis of the canonical NFkB components p65 and p50 showed a significant reduction of both proteins in the nuclear fraction in the LMX1B-expressing cells (Figure 5e, Supplementary Figure 4C ). Taken together, these results demonstrate that overexpression of LMX1B induces transcriptional activation of the NFkB pathway, consequently increases the migratory ability of OVCA cells and promotes tumor progression. 
DISCUSSION
The complexity of genomic aberrations in human cancers hampers identification of genes that drive tumorigenesis. Using comparative oncogenomic analysis, we have identified LMX1B as a novel oncogene and have provided functional and mechanistic evidence that supports the role of LMX1B in OVCA progression. In agreement with our in vitro and in vivo data, expression analysis in primary serous human ovarian cancers revealed that higher levels of LMX1B expression correlate with poor outcome.
LMX1B belongs to the LIM-homeodomain (LIM-HD)-containing family of transcription factors. To date, 12 LIM-HD transcription factors have been characterized in mammals (LHX1-9, ISL1-2, LMX1A and LMX1B). They have key regulatory functions in cell-type specification during development and many of them are associated with human diseases. 30, 31 LIM-HD proteins feature two LIM domains in their amino termini and a central HD. The HD is a highly conserved 60-amino-acid domain that mediates the binding of specific DNA elements within target genes. 32 The LIM domain is a conserved cystine-and histidine-rich domain of 50-60 amino acids, consisting of two tandemly repeated zinc fingers. The LIM domain is a multifunctional protein-protein interaction domain that mediates interactions with other transcription factors as well as transcriptional cofactors that do not bind directly to DNA. 30 In humans, LMX1B heterozygous mutations are associated with nail-patella syndrome. Nail-patella syndrome is an autosomal dominant condition characterized by hypoplastic nails, hypoplastic or absent patellae, joint abnormalities with contractures, iliac horns (70-90% of patients), nephropathy (40% of patients) and glaucoma (10% of patients). 33 Mutations in LMX1B concentrate within the exons encoding the LIM domains (LIM1 44%, LIM2 38%) and the HD (18%). 34 Functional characterization of the LMX1B mutants has been reported to have diminished transcriptional activity and loss of DNA-binding ability. 26, 35 However, in cancer, it is likely that enhanced expression of LMX1B is achieved via alternative mechanisms including epigenetic alterations and is sufficient to promote cancer progression.
Activation of the NFkB pathway has been known to have a critical role in OVCA. 29, 36 In our study, gene set enrichment analysis of differentially expressed genes in LMX1B-overexpressing cells identified response to cytokine stimulus gene set with the highest median fold-change. This gene set included 36 genes including IL6, IL8, ILF3, IL11, IL24, NFKBIA, NFKB1, NFKBIE, INSIG1, SOD2, STIL, PTGS1, PTGS2 and BCL6, which are associated with the NFkB pathway (Supplementary Table 2) . 37, 38 To further evaluate the LMX1B-induced NFkB activity in the production of proinflammatory cytokines, including IL6 and IL8, we blocked the NFkB activity in OVCAR5 and OV90 cells using QNZ (an NFkB transactivation inhibitor). QNZ treatment resulted in significantly reduced levels of IL6 and IL8 after 24 h compared with control cells (Figure 5c, Supplementary Figure 4C ) as well as decreased LMX1B as an oncogene in ovarian cancer L He et al their migratory ability (Figure 5d) . Inhibition of the NFkB activity resulted in the reduction in NFkB components p65 and p50 in the nucleus (Figure 5e ). These results demonstrate that LMX1B mediates its oncogenic effect partly by inducing the NFkB pathway and accelerating tumor progression. Further work is necessary to show whether LMX1B mediates its effect through promoter binding or through cofactors.
Cytokines are critical components of inflammation participating in the interaction between the tumor cells and the microenvironment. The mechanisms of inflammation-mediated tumor promotion involve secretion of specific cytokines by both inflammatory and tumor cells as well as activation of transcription factors NFkB and STAT3. These transcription factors activate genes responsible for cell survival, proliferation, angiogenesis, invasiveness and production of cytokines. [39] [40] [41] NFkB belongs to a family of transcription factors that regulate the secretion of many inflammatory cytokines and the prostaglandin biosynthetic pathway. It also regulates the expression of antiapoptotic proteins and angiogenic factors. 42, 43 In our study, LMX1B-expressing cells did not show enhanced proliferation or anchorage-independent growth compared with GFP-expressing cells in vitro; however, there was a significant enhancement in tumor growth in vivo. We believe, that in vivo, there was a considerable interaction between the tumor and the stroma and the proinflammatory cytokines IL6, IL8 and IL11 along with PTGS1, PTGS2 and BCL6 create a microenvironment ideal for tumor growth in an accelerated manner. Thus explains the discrepancy between in vitro and in vivo results.
In addition, we identified many other gene sets that belong to different pathways such as cell motion (CFL1, ACTR2 and ABI2), G-protein-coupled receptors (RSG4 and ARRB1), peptidase activity (MMP3, CD44, SPARC and TIMP3), PPAR signaling pathway (CD36), cell-cell signaling (STC1) 44 and brain development (BMP4, DLX2, BPTF and FOXC1). 45 Further work is necessary to evaluate the potential role of these pathways in LMX1B-mediated tumor progression.
To date, B400 cancer genes, corresponding to 2% of proteincoding genes in the human genome have been identified primarily through cytogenetic analyses (fusion genes), systematic sequencing of exons (oncogenes, protein complexes involved in chromatin restructuring and maintenance of cytosine methylation) and high-throughput DNA copy number analysis (amplifications and homozygous deletions). 46 The process of identifying 'driver genes' is complicated partly due to the complex structural rearrangements in ovarian cancers and the involvement of large genomic segments spanning megabases of DNA sequences and multiple genes. We believe that comparative oncogenomic approach is useful as a cancer-gene discovery tool for identification of genes that are altered at the DNA copy number level. Using this approach, we have for the first time demonstrated that LMX1B is a novel oncogene and that it has key roles in OVCA progression. (Table 1) ; (b) qRT-PCR results for selected NFkB and non-NFkB genes in LMX1B-overexpressing cells compared with GFP control; (c) qRT-PCR was performed on the same genes as shown in Figure 5b using RNA from OVCAR5 and OV90 cells with ectopic expression of LMX1B or GFP treated with NFkB inhibitor QNZ for 24 h. Expression of the NFkB pathway genes was severely affected, whereas expression of non-NFkB genes DTL, ERBB3 and FOXC1 was not affected confirming that LMX1B-induced NFkB leads to the production of inflammatory cytokines; (d) Boyden chamber migration assay of cells after 24 h of 20 nM QNZ treatment showed up to 50% reduction in their migratory ability, confirming that LMX1B-induced NFkB activation accelerates tumor cell invasion (*P ¼ 0.003), error bars represent mean±s.d. from triplicate experiments; (e) western blot analysis showing reduction of nuclear NFkB components p65 and p50 after blocking NFkB activity with QNZ. Cross-examination of compartment protein extraction as well as loading is indicated by GAPDH (cytoplasmic marker) and Histone H3 (nuclear marker).
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MATERIAL AND METHODS
Cell lines
Derivation of genetically defined mouse OVCA lines is described in the study by Xing and Orsulic 14 and summarized in Supplementary Table 1 . Mouse OVCA lines and NIH3T3 cells were maintained in DMEM/F12 containing 10% fetal bovine serum, 100 IU/ml penicillin and 100 mg/ml streptomycin (Invitrogen, Grand Island, NY, USA). Human OVCA cell lines OVCAR5, OV90, TOV112D were obtained from the American Type Culture Collection (Manassas, VA, USA). Immortalized non-tumorigenic ovarian surface epithelial cell line T29 was provided by Jinsong Liu, MD Anderson Cancer Center. 47 All human cells were maintained in RPMI medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin and 100 mg/ml streptomycin. aCGH analysis Genomic DNA was isolated from 10 mouse ovarian cell lines using a routine protocol. Samples were profiled on the 44K Agilent mouse genome oligonucleotide array. DNA labeling, array hybridization, washing and image processing were performed following previously published protocol. 48 To facilitate identification of DNA copy number aberrations, a log2 ratio of þ 1/ À 1 was used as a cutoff, which was based on control hybridizations.
Fluorescence in situ hybridization analysis for aCGH data validation
To validate the DNA copy number alterations detected by aCGH, two-color fluorescence in situ hybridization was performed on cell lines following 49 The BAC clone RP23-65G6 containing Lmx1b was purchased from Invitrogen and validated by PCR screening. For fluorescence in situ hybridization, RP23-65G6 was labeled in Cy3-dUTP and the control clone RP23-60M5 mapping to 2qH4 was labeled in FITC-dUTP.
Expression profiling
RNA from human ovarian cell lines OVCAR5 and OV90, transduced with either LMX1B cDNA or GFP control was isolated using Qiagen RNeasy kit (Qiagen, Valencia, CA, USA). Generation of complimentary ribo nucleic acid (cRNA) and expression profiling was performed following the published protocol. 28 Differential expression was considered significant at a P-value of p0.001.
Patient sample acquisition and processing
Human serous type OVCA samples were obtained from the Massachusetts General Hospital Gynecologic Tissue Repository. Use of tissues for this study was approved by the Institutional Review Board. RNA/DNA was isolated from frozen tumor samples with 480% tumor cells.
Quantitative real-time PCR
For quantitating mRNA expression, mouse and human tumors and human cell lines were lysed in Trizol reagent (Invitrogen). RNA was isolated using QIAGEN RNeasy kit and qRT-PCR was done in triplicate using gene-specific primers and the SYBR Green PCR Master Mix and SYBR Green RT-PCR Reagents (Applied Biosystems, Grand Island, NY, USA).
For human samples, GAPDH was utilized as internal control; the level was then normalized against T29 cells. To calculate the relative expression for each gene, the 2 À DDCT method was used. The qRT-PCR primer sequences for LMX1B are as follows: forward primer CACAGCAGCA-GATCGTGG and reverse primer AGCAGTCGCTGAGGCTGG. The same primer set was used for both human and mouse qRT-PCR.
Cell migration assay
Boyden chamber-based migration assay was performed in a 24-well cell culture insert with 8.0 mm pore size PET membrane (BD Biosciences, San Jose, CA, USA). Cells were resuspended at a density of 100 000 cells per ml in basal medium (RPMI1640 þ 0.1% fetal bovine serum) and plated in triplicate in 350 ml into the upper chamber. The bottom chamber contained 500 ml of basal media with chemoattractant (10% fetal bovine serum). After cells were plated for 4 h, the insert was removed and wiped with a cotton swab to dislodge the non-migrated cells. Migrated cells on the underside were fixed and stained with Diff-Quick Stain Set (Dade Behring, Deerfield, IL, USA) and quantified by counting under Â 40 magnification (field covers 480% of the membrane).
LMX1B cloning and retrovirus-mediated gene transduction
Human cDNA clone for LMX1B was obtained from Open Biosystems (Pittsburgh, PA, USA), and the coding region was PCR-amplified and cloned into pWZL retroviral vector. Final constructs were verified by sequencing. C1, C2, BR5, NIH3T3, OVCAR5 and OV90 cells were transduced with LMX1B or GFP via retrovirus-mediated gene transfer as previously described. 15 Subsequently, cells were drug selected for 10-15 days. LMX1B overexpression was confirmed by qRT-PCR.
For western blot analysis of exogenous LMX1B protein, LMX1B ORF was cloned into pCMV6 vector with C-terminal FLAG tag from OriGene Technologies (Rockville, MD, USA). This construct was used for transient expression of tagged LMX1B protein along with short hairpins against LMX1B (by cotransfection with sh-LMX1B-B10 or sh-LMX1B-C01) to monitor the knockdown effect at the protein level using a monoclonal anti-FLAG antibody (Sigma, St Louis, MO, USA).
Lentiviral shRNA constructs against human LMX1B were obtained from the Broad RNAi Consortium in pLKO-puro vector. Viral production and infection was carried out according to the instructions provided by the Consortium. The knockdown efficiency was tested by qRT-PCR. Two constructs, sh-LMX1B-B10 (target sequence: GAACCAAAGAGCAAAGAT GAA) and sh-LMX1B-C01 (target sequence: GCTACGCAAGGGCGACGAATT), that showed significant knockdown effect were chosen for further studies. Transduced cells were passaged no more than two times before injection into NOD/SCID mice, expression analysis or in vitro assays.
In vivo tumorigenicity assays
All experiments utilizing mice were reviewed and approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee and were performed in strict accordance with the NIH Guide for the Care and Use of Laboratory Animals. Six to eight week old female nude mice (Charles River Laboratories, Wilmington, MA, USA) were used for xenograft experiment of mouse cell lines. Six to twelve week old female NOD/SCID mice (strain NOD.CB17-Prkdcscid/J, Jackson Laboratory, Bar Harbor, ME, USA) were used for xenograft experiment of human cell lines. Briefly, a total of 5 Â 10 5 cells were suspended in 1:1 PBS/Matrigel (BD Biosciences, San Jose, CA, USA) and subcutaneously injected into the dorsal side of mice. Control animals were simultaneously injected with 1:1 PBS/Matrigel only. Tumor development was assessed weekly. The same number of cells were used for intraperitoneal injections.
Statistical analysis
Differences between LMX1B expression levels in subgroups based upon T29 cells were assessed using two-sample t-tests. Kaplan-Meier survival analysis was used to estimate the survival difference between low and high expressors defined using the median expression level as cutoff. Values were considered statistically significant (Po0.05), except for the microarray analysis, where significance was set at Pp0.001. Tumor weight comparison was carried out by paired Student's t-test.
